NCT02328014View on ClinicalTrials.gov

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 20, 2014

Primary Completion Date

June 1, 2020

Study Completion Date

April 1, 2026

Conditions
Non-Hodgkins LymphomaMultiple MyelomaB-All
Interventions
DRUG

Acalabrutinib

Oral

DRUG

ACP-319

Oral

Trial Locations (7)

14642

Research Site, Rochester

20892

Research Site, Bethesda

37203

Research Site, Nashville

78705

Research Site, Austin

92868

Research Site, Orange

97239

Research Site, Portland

98109

Research Site, Seattle

Sponsors

Lead Sponsor

Acerta Pharma BV

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Acerta Pharma BV

INDUSTRY

NCT02328014 - Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies | Biotech Hunter | Biotech Hunter